Ambys Medicines
David Russell, M.D., Ph.D. is the former CSO and co-founder of Universal Cells Inc., a Professor in the Department of Medicine at the University of Washington in Seattle, and a past president of the American Society of Gene and Cell Therapy. His research career has focused on developing improved methods for manipulating the mammalian genome, with the goal of creating new genetic therapies. David received clinical training in internal medicine, hematology/oncology, and bone marrow transplantation. His laboratory has made major contributions in the fields of recombinant adeno-associated virus (rAAV) vectors, vector integration, insertional mutagenesis, and the genetic engineering of human stem cells. David discovered the rAAV-mediated gene-editing technology licensed by Universal Cells and has used this approach to engineer HLA genes in human stem cells.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.